Abstract
This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the associated risk of ventricular arrhythmia and fibrillation. The molecular characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation. The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to determine structure-activity relations (SAR) within chemical series. More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chemical series is a viable strategy to reduce or eliminate hERG activity. Despite a critical need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.
Keywords: hERG, Ikr, action potential, repolarization reserve, transmural dispersion of repolarization (TDR), QT prolongation, torsades de Pointes (TdP)
Current Topics in Medicinal Chemistry
Title: The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview
Volume: 8 Issue: 13
Author(s): Armando A. Lagrutta, Elena S. Trepakova and Joseph J. Salata
Affiliation:
Keywords: hERG, Ikr, action potential, repolarization reserve, transmural dispersion of repolarization (TDR), QT prolongation, torsades de Pointes (TdP)
Abstract: This review summarizes current knowledge of the cardiac rapidly activating delayed rectifier potassium current (IKr), and its connection to drug-acquired QT prolongation and the associated risk of ventricular arrhythmia and fibrillation. The molecular characterization of hERG as the structural correlate of IKr and the link between inherited long QT and the KCNH2 gene (hERG), have facilitated mechanistic studies of drug-acquired QT prolongation. The development of high throughput assays to evaluate drug effects on hERG has provided an avenue to determine structure-activity relations (SAR) within chemical series. More than 10 years of collective data and structural considerations support the notion that hERG is an unusually promiscuous target among potassium channels, but that defining SAR within a chemical series is a viable strategy to reduce or eliminate hERG activity. Despite a critical need to minimize drug effects on hERG, one should always keep in mind that hERG is not the only structural correlate of QT prolongation, and that QT prolongation is a sub-optimal biomarker for ventricular arrhythmia and fibrillation.
Export Options
About this article
Cite this article as:
Lagrutta A. Armando, Trepakova S. Elena and Salata J. Joseph, The hERG Channel and Risk of Drug-Acquired Cardiac Arrhythmia: An Overview, Current Topics in Medicinal Chemistry 2008; 8 (13) . https://dx.doi.org/10.2174/156802608785700016
DOI https://dx.doi.org/10.2174/156802608785700016 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Vanilloid Transient Receptor Potential Cation Channels: An Overview
Current Pharmaceutical Design Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Effects of an Acute Treatment with L-Thyroxine on Memory, Habituation, Danger Avoidance, and on Na+, K+-ATPase activity in Rat Brain
Current Neurovascular Research Long Range Regulatory Sequences Delimited by Progressive Deletions of a Mouse Nkx2-5-GFP-BAC Clone: A New Approach to Identify Distal Gene Regulators in Evolutionarily Conserved Non-Coding Sequences
Current Genomics FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Stress Echocardiography
Current Pharmaceutical Design Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets